Togo
Tuberculosis profile
| High HIV burden |
Population  2013 6.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.81 (0.51–1.1) 12 (7.5–16)
Mortality (HIV+TB only) 0.38 (0.3–0.47) 5.6 (4.4–6.9)
Prevalence  (includes HIV+TB) 7.1 (3.8–11) 104 (56–166)
Incidence  (includes HIV+TB) 5 (4.4–5.6) 73 (64–82)
Incidence (HIV+TB only) 1.1 (0.96–1.2) 16 (14–18)
Case detection, all forms (%) 52 (47–59)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 26 (15–40)
MDR-TB cases among notified pulmonary
TB cases
40 (2–110) 44 (25–68)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 934   118
Pulmonary, clinically diagnosed 155   0
Extrapulmonary 393   0
       
Total new and relapse 2 600    
Previously treated, excluding relapses 50    
Total cases notified 2 650    
Among 2 600 new and relapse cases:
85 (3%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 8 (<1%) 134 (80%) 142
Laboratory-confirmed RR-/MDR-TB cases     19
Patients started on MDR-TB treatment     12
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 581 (97)
HIV-positive TB patients 519 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 461 (89)
HIV-positive TB patients on antiretroviral therapy (ART) 372 (72)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 86
Previously treated cases registered in 2012 83
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 25
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 19%
% Funded internationally 80%
% Unfunded <1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-06 Data: www.who.int/tb/data